Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF)
- Tryp Therapeutics is a pharmaceutical company focused on establishing new drug candidates that will provide effective alternatives to established treatments for responding to medical conditions with largely unmet needs
- The company is preparing to launch a clinical trial with a 25mg synthetic psychedelic drug candidate, TRP-8802, to determine its efficacy and safety in treating select eating disorders in combination with psychotherapy
- Tryp recently announced that its educational partner, Fluence, has completed training of the psychotherapists who will be involved in administering the drug candidate to help establish minimal variability in the data outcomes and grant the patients the best possible experience
- Investment banking services provider, Ladenburg Thalmann & Co., announced on Aug. 26 that it has initiated coverage on Tryp with a “buy” rating
is approaching the launch of its phase 2a clinical trial that will use synthetic psilocybin (a psychedelic drug derived from certain mushrooms) in combination with psychotherapy for a select class of overeating disorders.
Tryp has continued to execute on its mission to develop successful treatments with increased efficacy for medical conditions with high unmet needs. The phase 2a trial, to be conducted at the University of Florida (“UF”), will determine safety and efficacy of psilocybin on hyperphagia — a condition in which the patients never feel full, so they are continually wanting to eat.
“The research we’re actually going to be doing at the University of Florida with psilocybin is focusing on a little bit more intense problems than just eating disorders,” said pediatric eating disorders expert Dr. Jennifer Miller, who will be the trial’s principal investigator, during an interview with The Dales Report in May (https://ibn.fm/XDAVY
). “Ultimately, of course, we hope it will help people with overall eating disorders, but first we’re going to focus on people with specific neurologic causes of those eating disorders … for treatment of a select chronic eating disorder called Prader-Willi Syndrome (‘PWS’).”
The hyperphagia trial will also target hypothalamic obesity eating disorder — the result of the removal of a brain tumor — and binge eating disorder. TRP-8802, an off-the-shelf synthetic psilocybin active pharmaceutical ingredient (“API”) will aim to shake up the clinical thinking on how to deal with such neurological conditions and prepare Tryp for further studies using their novel, trademarked drug candidate, TRP-8803.
“All of the currently available approved obesity and eating disorder medications are daily medications: you stop taking them, you stop having the efficacy,” Miller said. “Our hope is with psilocybin, … (that) once- or twice-a-year treatments will allow these neural networks to rewire themselves and provide a more chronic treatment, which doesn’t exist right now. … None of the currently available treatments or even past available treatments touch their appetite and fullness.”
On Aug. 24, Tryp announced that psychedelic therapy educational platform partner Fluence, has completed the training of the psychotherapists who will be involved in the phase 2a trial by assisting and overseeing dosing sessions of the psychedelics (https://ibn.fm/eCpNN
“Psychotherapy is an integral part of Tryp’s novel treatment methods to create the proper mindset for the neuroplasticity benefits of psilocybin to take full effect,” the news release states. “Participants will undergo preparatory psychotherapy sessions with trained therapists leading to two dosing sessions in the upcoming phase 2a clinical trial for eating disorders. … Following the administration of the drug, patients will also benefit from multiple integration sessions with the therapists.”
To ensure the scientific viability of the trials, it is important to establish definitive guidelines and training to minimize variability and grant the patients the best possible experience. The training will also be adapted to subsequent clinical trials, such as using Tryp’s API to treat fibromyalgia and other chronic pain indications.
Tryp’s efforts have caught the attention of investment banking and capital markets products and services provider Ladenburg Thalmann & Co. Inc., which serves investors who are specifically focused on health care and life sciences companies. Ladenburg Thalmann announced on Aug. 26 that it had initiated coverage on Tryp with a buy rating (https://ibn.fm/9aFSD
In its research note, Ladenburg noted that psychedelics have recently outperformed approved prescription treatments for major depressive disorder and posttraumatic stress disorder, leading to the advisement that psilocybin-assisted psychotherapy may provide an appropriate response for helping people with eating disorders “benefit from a disconnect of the brain’s neural connections, allowing for new connections and behaviors distinct from current memories and feelings.”
For more information on Tryp Therapeutics, visit the company’s website at www.TrypTherapeutics.com
NOTE TO INVESTORS:
The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks
designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Do you have questions or are you interested in working with PNW? Ask our Editor
San Francisco, California
PsychedelicNewsWire is part of the InvestorBrandNetwork